Sunday, Aug 09, 2020 | Last Update : 12:13 AM IST

137th Day Of Lockdown

Maharashtra49026232728117092 Tamil Nadu2850242275754690 Andhra Pradesh2069601204641842 Karnataka164924842322998 Delhi1427231282324082 Uttar Pradesh113378668341981 West Bengal89666630601954 Bihar7179446294400 Gujarat68855517922604 Assam5549737225132 Rajasthan4941835186763 Odisha4255028698292 Haryana4005433444467 Madhya Pradesh3729827621962 Kerala3170019147103 Jammu and Kashmir2392716218449 Punjab2193014040539 Jharkhand165427503154 Chhatisgarh11408831987 Uttarakhand89015731112 Goa7947559570 Telangana751354330615 Tripura6014408437 Puducherry5123291475 Manipur3466192610 Himachal Pradesh3206200813 Nagaland26578247 Arunachal Pradesh204913263 Chandigarh137482023 Meghalaya10234236 Sikkim8544061 Mizoram5672890
  Business   Companies  13 Jul 2020  Glenmark Pharma cuts price of COVID-19 drug Favipiravir to Rs 75/tablet

Glenmark Pharma cuts price of COVID-19 drug Favipiravir to Rs 75/tablet

PTI
Published : Jul 13, 2020, 2:53 pm IST
Updated : Jul 13, 2020, 2:53 pm IST

Glenmark Pharmaceuticals had launched antiviral drug Favipiravir, under the brand name FabiFlu, last month at a price of Rs 103 per tablet

 Glenmark Pharmaceuticals on Monday said it has cut price of its antiviral drug Favipiravir by 27 pc to Rs 75/tablet. (Photo- Twitter)
  Glenmark Pharmaceuticals on Monday said it has cut price of its antiviral drug Favipiravir by 27 pc to Rs 75/tablet. (Photo- Twitter)

New Delhi: Drug firm Glenmark Pharmaceuticals on Monday said it has cut price of its antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19, by 27 per cent to Rs 75 per tablet.

Glenmark Pharmaceuticals had launched FabiFlu last month at a price of Rs 103 per tablet.

 

In a regulatory filing Glenmark announced a price reduction of 27 per cent for FabiFlu. The new maximum retail price (MRP) is Rs 75 per tab, it said.

"The price reduction has been made possible through benefits gained from higher yields and better scale, as both the active pharmaceutical ingredient (API) and formulations are made at Glenmark's facilities in India, the benefits of which are being passed on to patients in the country," the filing said.

"Our internal research shows us that we launched FabiFlu in India at the lowest market cost as compared to the cost of Favipiravir in other countries where it is approved. And now we hope that this further price reduction will make it even more accessible for patients across the country," Glenmark Pharmaceuticals Senior Vice President and Head – India business Alok Malik said.

 

Further, the company has commenced a post marketing surveillance (PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in 1,000 patients that are prescribed with the oral antiviral, as part of an open label, multicenter, single arm study, the filing added.

"We expect this post marketing surveillance study to shed more light on the drug's clinical effectiveness and safety in a large cohort of patients prescribed FabiFlu," Malik added.

On June 20, Glenmark announced that it received manufacturing and marketing approval from India's drug regulator for FabiFlu, making it the first oral Favipiravir-approved medication in India for the treatment of mild to moderate COVID-19.

 

Glenmark has also completed the phase 3 clinical trial with Favipiravir (FabiFlu) in mild to moderate COVID-19 patients in India. The trial results will be available shortly, the company said.

Glenmark is also conducting another phase 3 clinical trial to evaluate the efficacy of two antivirals drugs Favipiravir and Umifenovir as a combination therapy in moderate hospitalised adult COVID-19 patients in India.

Shares of Glenmark Pharma were trading 1.34 per cent lower at Rs 421.00 apiece on BSE.

Tags: coronavirus, glenmark pharamceuticals, health, covid-19 drug, favipiravir, fabiflu
Location: India, Delhi, New Delhi